Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES
Print Format
Change Text Size:

BRIEF-Schrödinger Reports New Preclinical Data Supporting Advancement Of Its Wee1 Inhibitor Program

BY Reuters
— 7:35 AM ET 04/12/2022

April 12 (Reuters) - Schrodinger Inc (SDGR):

* SCHRÖDINGER REPORTS NEW PRECLINICAL DATA SUPPORTING ADVANCEMENT OF ITS WEE1 INHIBITOR PROGRAM AT AMERICAN ASSOCIATION OF CANCER RESEARCH 2022 ANNUAL MEETING

* SCHRODINGER INC (SDGR) - HIGHLY SELECTIVE AND STRUCTURALLY-DISTINCT WEE1 INHIBITORS DEMONSTRATE STRONG ANTI-TUMOR ACTIVITY IN TUMOR MODELS

* SCHRODINGER INC (SDGR) - ON TRACK TO SELECT A WEE1 DEVELOPMENT CANDIDATE IN 2022 Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More SDGR News
Copyright 1998–2022 FMR LLC. 
All rights reserved. 
Close